Evolent Health (NYSE:EVH) Now Covered by Needham & Company LLC

Needham & Company LLC began coverage on shares of Evolent Health (NYSE:EVH) in a research note issued to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $15.00 price target on the technology company’s stock.

A number of other analysts have also recently weighed in on EVH. Oppenheimer dropped their price objective on shares of Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $38.00 to $16.00 in a report on Friday, November 8th. Citigroup decreased their price objective on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Barclays cut their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, KeyCorp assumed coverage on Evolent Health in a research note on Friday, October 11th. They issued an “overweight” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $23.92.

Evolent Health Trading Down 0.2 %

Shares of NYSE EVH opened at $12.57 on Friday. Evolent Health has a 12-month low of $10.53 and a 12-month high of $35.00. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock’s 50 day simple moving average is $13.13 and its 200 day simple moving average is $21.09. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -13.81 and a beta of 1.45.

Hedge Funds Weigh In On Evolent Health

Hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. boosted its stake in shares of Evolent Health by 3.2% during the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock worth $298,000 after acquiring an additional 480 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Evolent Health by 8.3% in the 2nd quarter. Rhumbline Advisers now owns 180,059 shares of the technology company’s stock valued at $3,443,000 after purchasing an additional 13,867 shares during the period. Arizona State Retirement System increased its stake in Evolent Health by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock worth $556,000 after purchasing an additional 649 shares in the last quarter. Quest Partners LLC acquired a new stake in Evolent Health during the 2nd quarter worth about $87,000. Finally, Federated Hermes Inc. purchased a new stake in Evolent Health during the second quarter valued at about $6,273,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.